Overall, the reported data indicate that SP-D is a robust marker for treatment effects, but that the utility of circulating SP-D as marker for prediction of COPD exacerbation may be limited, despite induction of serum SP-D in the acute phase. Here, SFTPD is linked to chronic obstructive pulmonary disease.